- Report
- February 2024
- 175 Pages
Global
From €4767EUR$5,000USD£4,073GBP
- Report
- February 2024
- 175 Pages
Global
From €4767EUR$5,000USD£4,073GBP
- Report
- February 2024
- 120 Pages
Global
From €4529EUR$4,750USD£3,869GBP
- Report
- October 2023
- 85 Pages
United States
From €4529EUR$4,750USD£3,869GBP
- Report
- August 2022
- 111 Pages
Global
From €4529EUR$4,750USD£3,869GBP
- Report
- March 2021
- 45 Pages
Global
From €2379EUR$2,495USD£2,032GBP
- Report
- February 2020
- 137 Pages
Global
From €7623EUR$7,995USD£6,513GBP
- Report
- March 2021
- 52 Pages
Global
€1257EUR$1,318USD£1,074GBP
- Report
- February 2020
- 150 Pages
Asia Pacific
From €8576EUR$8,995USD£7,327GBP
Axial Spondyloarthritis (axSpA) is a chronic inflammatory disorder of the spine and sacroiliac joints, which is classified as a type of arthritis. It is a form of spondyloarthritis, a group of diseases that affect the spine and other joints. Symptoms of axSpA include pain and stiffness in the lower back, hips, and other joints, as well as fatigue and inflammation. Treatment options for axSpA include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologic agents. Allergy and Immunology specialists are often involved in the diagnosis and management of axSpA, as the condition is believed to be caused by an autoimmune response.
Companies in the axSpA market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Show Less Read more